{"disease":{"id":"pleural-mesothelioma-malignant-advanced","name":"pleural mesothelioma malignant advanced"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03762018","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":false},{"nct_id":"NCT02991482","title":"PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":true},{"nct_id":"NCT03507452","title":"First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07126509","title":"Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of Chicago","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}